Latest news
{{'2026-04-20T09:19:50Z' | dateFormatFilter}}
Novo Nordisk: Etavopivat is the first in a new class of drugs to meet both co-primary endpoints in the phase 3 HIBISCUS trial, substantially reducing vaso-occlusive crisis events and improving haemoglobin response in sickle cell disease
{{'2026-04-14T06:00:00Z' | dateFormatFilter}}
Novo Nordisk and OpenAI partner to transform how medicines are discovered and delivered
{{'2026-04-09T12:28:19Z' | dateFormatFilter}}
Novo Nordisk A/S: Wegovy® injection becomes first GLP-1 weight-loss treatment approved for 48-hour controlled-temperature delivery in the EU
Investors
Share price
{{priceData.date}} {{priceData.time}}
{{priceData.currentPrice}}
{{priceData.currency}}
Go to stock watch
{{priceData.change}} {{priceData.currency}}
